Related Experiment Video
Updated: Jul 30, 2025
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
[A new approach to etiotropic therapy ARVI in children]
A U Sabitov1, O P Kovtun1, E V Esaulenko2
1Ural State Medical University.
Insights
Riamilovir (Triazavirin®) effectively and safely treats acute viral respiratory infections (ARVI) in children aged 12-17. The study confirmed reduced illness duration and no serious adverse events, recommending its use in pediatric ARVI treatment.
Area of Science:
- Pediatrics
- Virology
- Pharmacology
Background:
- Acute viral respiratory infections (ARVI) are common in children.
- Effective etiotropic therapies for pediatric ARVI are needed.
Purpose of the Study:
- To confirm the efficacy and safety of riamilovir (Triazavirin®) in children aged 12-17 with ARVI.
- To evaluate riamilovir's impact on disease duration and adverse events.
Main Methods:
- A multicenter study involving 269 pediatric patients diagnosed with ARVI.
- Etiology confirmed by PCR; patients enrolled within 36 hours of symptom onset.
- Informed consent obtained from patients and parents/guardians.
Main Results:
- Riamilovir (Triazavirin®) demonstrated efficacy and safety in treating pediatric ARVI.
- A significant decrease in disease duration was observed compared to the control group.
- No serious adverse events were reported during the study.
Conclusions:
- Riamilovir (Triazavirin®) is highly effective, safe, and well-tolerated for treating ARVI in children aged 12-17.
- Clinical practice recommendation for riamilovir as etiotropic therapy in this age group.
- Supports the use of riamilovir for its proven efficacy and safety profile.
Aim:
Confirmation of the efficacy and safety of the drug riamilovir (Triazavirin®), 100 mg capsules, in children aged 12-17 years with the diagnosis of acute viral respiratory infection (ARVI).
Materials And Methods:
The multicenter study included 269 patients diagnosed with acute viral respiratory infection (ICD-10 code: J00, J02, J02.9, J04, J04.0, J04.1, J04.2, J06, J06.0, J06.9) in the presence of clinical manifestations and confirmation of the etiology of the disease by laboratory tests (PCR method). Patients were included in the study after one of the patient's parents/adoptive parents and the patient signed an informed consent to participate in the study. The interval between the appearance of the first symptoms of the disease and the inclusion of the patient in the study did not exceed 36 hours.
Results:
As a result of a clinical study, the efficacy and safety of treatment with riamilovir (Triazavirin®) in sick children aged 12-17 years with a diagnosis of ARVI was shown. A decrease in the duration of the disease was shown when using the drug riamilovir (Triazavirin®) compared with the control group. No serious adverse events were detected during the study.
Conclusion:
As a result of the conducted clinical study, the high efficacy, safety and good tolerability of the drug riamilovir in the treatment of children aged 12-17 years with a diagnosis of ARVI was established. It is recommended to use the drug riamilovir in clinical practice as an etiotropic therapy in children aged 12-17 years with a diagnosis of ARVI due to its high efficacy and safety.
More Related Videos
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
